Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

Full Prescribing Info

Indications/Uses

Lucentis is indicated in adult for: the treatment of neovascular (wet) age-related macular degeneration (AMD); the treatment of visual impairment due to diabetic macular edema (DME); the treatment of moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR); the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO); the treatment of visual impairment due to choroidal neovascularization (CNV); the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).
Lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (ROP) (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).

Lucentis Indications/Uses

ranibizumab

Manufacturer:

Novartis

Distributor:

DCH Auriga

Marketer:

IQVIA